Robidoux J, Simoneau L, St-Pierre S, Masse A, Lafond J
Gynecology-Obstetrics Department, Faculté de Médecine, Université de Montréal, Québec, Canada.
Endocrinology. 2000 Aug;141(8):2795-804. doi: 10.1210/endo.141.8.7601.
Neuropeptide Y (NPY) is a CRF secretagogue for human placental cells in culture. We have studied the involvement of intracellular calcium and calcium-dependent signaling in the NPY-induced CRF release in trophoblastic cells. The incubation of trophoblasts with NPY for 3 and 8 h led to a dose-dependent increase in CRF secretion. Also, NPY stimulated synthesis of this peptide hormone upon an 8-h incubation period. BIBP3226, a selective Y1 receptor antagonist, and pertussis toxin (PTX) eliminated these effects. NPY-stimulated CRF secretion was mostly prevented by loading cells with BAPTA-AM, suggesting that elevation of intracellular calcium is responsible for the increase of CRF secretion. However, this calcium chelator had no effect on CRF synthesis. Furthermore, U-73122, a phospholipase C-betas (PLC) inhibitor or xestospongin C, an inositol triphosphate receptor (InsP3-R) blocker, have partially prevented the effect of NPY on CRF synthesis and secretion. Therefore, the increase in CRF synthesis and secretion rely in part on the release of calcium from intracellular store. Interestingly, SKF 96365, an inhibitor of store operated calcium (SOC) influx, also partially blocked the NPY stimulatory effect on CRF release but not its synthesis, suggesting that calcium influx is also involved in this stimulation. In the syncytiotrophoblast, known to possess a NPY-activated protein kinase C (PKCs) activity, NPY also stimulated calcium calmodulin kinase II (CaMKII) and extracellular regulated kinase (ERK1/2) activities. In the present study, we observed that bisindolylmaleimide (BIM), a nonspecific PKCs inhibitor partially prevented the NPY-induced CRF release. On the other hand, autocamtide-2 related inhibitory peptide (AIP), a CaMKII inhibitor, prevented most of the stimulatory effect of NPY on both CRF synthesis and release. Go6976, an inhibitor of the conventional and mu PKCs and PD 098059, an inhibitor of the ERK cascade, had no effect on neither CRF synthesis nor release. Altogether, these results support a Y1 receptor-mediated PTX-sensitive induction on CRF synthesis and release by NPY from human placental trophoblasts. The stimulation of CRF synthesis by NPY seems to depend mainly on a PLC-beta to InsP3-R axis and on CaMKII activity. Also, the release of CRF depends on the PLC-beta to InsP3-R axis and CaMKII activity but also entails the participation of a calcium-independent PKCs.
神经肽Y(NPY)是培养的人胎盘细胞的促肾上腺皮质激素释放因子(CRF)促分泌剂。我们研究了细胞内钙和钙依赖性信号传导在滋养层细胞中NPY诱导的CRF释放中的作用。用NPY孵育滋养层细胞3小时和8小时导致CRF分泌呈剂量依赖性增加。此外,NPY在8小时孵育期刺激了这种肽激素的合成。选择性Y1受体拮抗剂BIBP3226和百日咳毒素(PTX)消除了这些作用。用BAPTA-AM使细胞内钙升高可大部分阻止NPY刺激的CRF分泌,这表明细胞内钙升高是CRF分泌增加的原因。然而,这种钙螯合剂对CRF合成没有影响。此外,磷脂酶C-β(PLC)抑制剂U-73122或肌醇三磷酸受体(InsP3-R)阻滞剂xestospongin C部分阻止了NPY对CRF合成和分泌的作用。因此,CRF合成和分泌的增加部分依赖于细胞内钙库释放钙。有趣的是,储存操纵性钙(SOC)内流抑制剂SKF 96365也部分阻断了NPY对CRF释放的刺激作用,但对其合成没有影响,这表明钙内流也参与了这种刺激。在已知具有NPY激活的蛋白激酶C(PKC)活性的合体滋养层细胞中,NPY还刺激了钙调蛋白激酶II(CaMKII)和细胞外调节激酶(ERK1/2)的活性。在本研究中,我们观察到非特异性PKC抑制剂双吲哚马来酰亚胺(BIM)部分阻止了NPY诱导的CRF释放。另一方面,CaMKII抑制剂自磷酸化钙调蛋白-2相关抑制肽(AIP)阻止了NPY对CRF合成和释放的大部分刺激作用。传统和μ型PKC抑制剂Go6976以及ERK级联抑制剂PD 098059对CRF合成和释放均无影响。总之,这些结果支持Y1受体介导的PTX敏感的NPY诱导人胎盘滋养层细胞合成和释放CRF。NPY对CRF合成的刺激似乎主要依赖于PLC-β至InsP3-R轴和CaMKII活性。此外,CRF的释放依赖于PLC-β至InsP3-R轴和CaMKII活性,但也需要非钙依赖性PKC的参与。